{"id":20594,"date":"2024-09-11T09:59:26","date_gmt":"2024-09-11T09:59:26","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/?p=20594"},"modified":"2024-09-11T09:08:18","modified_gmt":"2024-09-11T09:08:18","slug":"produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/","title":{"rendered":"Decentralized production of advanced therapies, the Car-T case"},"content":{"rendered":"

As the Observatory on Advanced Therapies reveals, “currently all Car-Ts on the market are obtained through a centralized production process”: the biological material taken from patients is sent to “a few highly specialized production workshops” and returns to the patients after a average time of 16-30 days<\/strong>. This wait, however, can easily be prolonged. According to Maria Whitman, global lead of pharma and biotech practice at consultancy ZS Associates, \u201cthe complexities of handling and transporting a biologic product, combined with the remoteness of a laboratory or hospital, can add days to , if not weeks.”<\/span><\/p>\n

Shorten the time<\/h2>\n

For centers located in the US, the process cannot even begin until the patient’s insurance company has given its approval, a process that can take up to two weeks. Limits in the production capacity of specialized companies can also have an impact: a study published in Frontiers in transplantation states that “patients often wait up to three weeks to access a manufacturing slot, the date on which the company can receive the biological product to start cell production.\u201d Naturally, during this period, the clinical conditions of many patients \u2013 who are often treated for very aggressive diseases, such as tumors \u2013 can significantly worsen.<\/strong><\/span><\/p>\n

The costs of centralized production<\/h2>\n

Centralized production also involves very high costs, partly due to the need for long special transportation and cryogenic storage of the product. According to various estimates, the cost of a Car-T infusion in the USA is around 4-500 thousand dollars, although the entire treatment (which includes preparation, infusion, hospitalization and management of side effects) can easily reach significantly higher amounts (in 2019 it was calculated as up to one million dollars). These are extremely burdensome costs for the healthcare systems of developed countries but which become prohibitive for the majority of the population of developing countries. As approved Car-T products and their indications continue to increase, scientists are urgently searching for alternative solutions.<\/span><\/p>\n

Different decentralization systems<\/span><\/h2>\n

The most popular model is the so-called “Point-of-care<\/strong>” (POC), which involves delocalized production near the health center where the patient receives the treatment (if not even inside it), significantly reducing the times and associated risks to cell transport. Two researchers from Harvard Medical School dedicated a study – published in Nature Biotechnology – to decentralized production (local manufacturing). According to their research, this solution \u201cwould greatly contribute to meeting growing demand\u201d but to ensure a successful implementation it is essential to leverage new technologies to ensure uniform product quality<\/strong> even in geographically dispersed facilities.<\/span><\/p>\n

The role of digitalisation<\/h2>\n

The article suggests the use of \u201cautomated cellular manufacturing systems, inline sensors, and process simulation to improve quality control and efficient supply chain management.\u201d There is no shortage of attempts to apply this theory: the startup Cellares, for example, presented its “factory in a box”, a completely closed system that uses software and robotics to automate the processing of cells by eliminating the variability and the risk of human error<\/strong>. Ori Biotech, on the other hand, is studying a robotic system that integrates automation and data analysis and promises to reduce the production time of Car-T therapies to just seven days.<\/span><\/p>\n

Work out the kinks<\/h2>\n

The presence of a multitude of production centers also introduces new problems, for example it makes it more difficult for regulatory authorities to carry out effective controls. According to the authors of the study in Nature, this obstacle could be overcome by involving other organizations, such as accreditation bodies, in control activities: according to their calculations, in the United States there are already 116 organizations that comply with the necessary standards. The agency could in turn conduct audits of representative samples of accredited establishments. Finally, they suggest changing regulatory standards \u201cto account for the unique characteristics of distributed manufacturing models.\u201d<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Decentralized manufacturing of advanced therapies, the Car-T case: a manufacturing system that extends beyond a few specialized facilities has the potential to significantly increase production capacity for advanced therapies but requires some systemic adjustments<\/p>\n","protected":false},"author":4,"featured_media":20592,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[769,844,796],"tags":[],"class_list":{"0":"post-20594","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-biodrugs-atmp-en","8":"category-manufacturing","9":"category-market"},"yoast_head":"\nDecentralized production of advanced therapies, the Car-T case - MakingPharmaIndustry<\/title>\n<meta name=\"description\" content=\"A manufacturing system that extends beyond a few specialized facilities has the potential to significantly increase production capacity for advanced therapies but requires some systemic adjustments\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Decentralized production of advanced therapies, the Car-T case - MakingPharmaIndustry\" \/>\n<meta property=\"og:description\" content=\"A manufacturing system that extends beyond a few specialized facilities has the potential to significantly increase production capacity for advanced therapies but requires some systemic adjustments\" \/>\n<meta property=\"og:url\" content=\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/\" \/>\n<meta property=\"og:site_name\" content=\"MakingPharmaIndustry\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-11T09:59:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/09\/AdobeStock_789664327-scaled.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1129\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Simone Montonati\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Simone Montonati\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/\"},\"author\":{\"name\":\"Simone Montonati\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/e8e6004901441203dcff5d6f8ec8d5c6\"},\"headline\":\"Decentralized production of advanced therapies, the Car-T case\",\"datePublished\":\"2024-09-11T09:59:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/\"},\"wordCount\":630,\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/09\/AdobeStock_789664327-scaled.jpeg\",\"articleSection\":[\"BioDrugs & ATMP\",\"MANUFACTURING\",\"Market\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/\",\"name\":\"Decentralized production of advanced therapies, the Car-T case - MakingPharmaIndustry\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/09\/AdobeStock_789664327-scaled.jpeg\",\"datePublished\":\"2024-09-11T09:59:26+00:00\",\"author\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/e8e6004901441203dcff5d6f8ec8d5c6\"},\"description\":\"A manufacturing system that extends beyond a few specialized facilities has the potential to significantly increase production capacity for advanced therapies but requires some systemic adjustments\",\"breadcrumb\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/#primaryimage\",\"url\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/09\/AdobeStock_789664327-scaled.jpeg\",\"contentUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/09\/AdobeStock_789664327-scaled.jpeg\",\"width\":2560,\"height\":1129},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/makingpharmaindustry.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Decentralized production of advanced therapies, the Car-T case\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/\",\"name\":\"MakingPharmaIndustry\",\"description\":\"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/e8e6004901441203dcff5d6f8ec8d5c6\",\"name\":\"Simone Montonati\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/2123f2fad86efe781cc2b3b753a84160f22a16f288a2a6462c482c735ca01425?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2123f2fad86efe781cc2b3b753a84160f22a16f288a2a6462c482c735ca01425?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2123f2fad86efe781cc2b3b753a84160f22a16f288a2a6462c482c735ca01425?s=96&d=mm&r=g\",\"caption\":\"Simone Montonati\"},\"url\":\"https:\/\/makingpharmaindustry.it\/en\/author\/simone-montonati\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Decentralized production of advanced therapies, the Car-T case - MakingPharmaIndustry","description":"A manufacturing system that extends beyond a few specialized facilities has the potential to significantly increase production capacity for advanced therapies but requires some systemic adjustments","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/","og_locale":"en_US","og_type":"article","og_title":"Decentralized production of advanced therapies, the Car-T case - MakingPharmaIndustry","og_description":"A manufacturing system that extends beyond a few specialized facilities has the potential to significantly increase production capacity for advanced therapies but requires some systemic adjustments","og_url":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/","og_site_name":"MakingPharmaIndustry","article_published_time":"2024-09-11T09:59:26+00:00","og_image":[{"width":2560,"height":1129,"url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/09\/AdobeStock_789664327-scaled.jpeg","type":"image\/jpeg"}],"author":"Simone Montonati","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Simone Montonati","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/#article","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/"},"author":{"name":"Simone Montonati","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/e8e6004901441203dcff5d6f8ec8d5c6"},"headline":"Decentralized production of advanced therapies, the Car-T case","datePublished":"2024-09-11T09:59:26+00:00","mainEntityOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/"},"wordCount":630,"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/09\/AdobeStock_789664327-scaled.jpeg","articleSection":["BioDrugs & ATMP","MANUFACTURING","Market"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/","url":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/","name":"Decentralized production of advanced therapies, the Car-T case - MakingPharmaIndustry","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/#primaryimage"},"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/09\/AdobeStock_789664327-scaled.jpeg","datePublished":"2024-09-11T09:59:26+00:00","author":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/e8e6004901441203dcff5d6f8ec8d5c6"},"description":"A manufacturing system that extends beyond a few specialized facilities has the potential to significantly increase production capacity for advanced therapies but requires some systemic adjustments","breadcrumb":{"@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/#primaryimage","url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/09\/AdobeStock_789664327-scaled.jpeg","contentUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2024\/09\/AdobeStock_789664327-scaled.jpeg","width":2560,"height":1129},{"@type":"BreadcrumbList","@id":"https:\/\/makingpharmaindustry.it\/en\/manufacturing\/produzione-decentralizzata-delle-terapie-avanzate-il-caso-car-t\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/makingpharmaindustry.it\/en\/"},{"@type":"ListItem","position":2,"name":"Decentralized production of advanced therapies, the Car-T case"}]},{"@type":"WebSite","@id":"https:\/\/makingpharmaindustry.it\/en\/#website","url":"https:\/\/makingpharmaindustry.it\/en\/","name":"MakingPharmaIndustry","description":"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/e8e6004901441203dcff5d6f8ec8d5c6","name":"Simone Montonati","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/2123f2fad86efe781cc2b3b753a84160f22a16f288a2a6462c482c735ca01425?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2123f2fad86efe781cc2b3b753a84160f22a16f288a2a6462c482c735ca01425?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2123f2fad86efe781cc2b3b753a84160f22a16f288a2a6462c482c735ca01425?s=96&d=mm&r=g","caption":"Simone Montonati"},"url":"https:\/\/makingpharmaindustry.it\/en\/author\/simone-montonati\/"}]}},"_links":{"self":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/20594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/comments?post=20594"}],"version-history":[{"count":1,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/20594\/revisions"}],"predecessor-version":[{"id":20595,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/20594\/revisions\/20595"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media\/20592"}],"wp:attachment":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media?parent=20594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/categories?post=20594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/tags?post=20594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}